[미국특허]
Adhesive treatment for oral fungal infection
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-013/02
A61K-031/74
출원번호
US-0898092
(2001-07-05)
발명자
/ 주소
Narang, Upvan
출원인 / 주소
Closure Medical Corporation
대리인 / 주소
Oliff & Berridge, PLC
인용정보
피인용 횟수 :
22인용 특허 :
64
초록▼
A method of treating or preventing oral fungal infection includes applying a polymerizable monomer adhesive composition to an area afflicted with or susceptible to oral fungal infection, optionally with at least one of an additional anti-fungal agent, and allowing the polymerizable monomer compositi
A method of treating or preventing oral fungal infection includes applying a polymerizable monomer adhesive composition to an area afflicted with or susceptible to oral fungal infection, optionally with at least one of an additional anti-fungal agent, and allowing the polymerizable monomer composition to polymerize to form a polymer film over the area.
대표청구항▼
1. A method of treating or preventing oral fungal infection, comprising:a) applying an adhesive composition comprising a polymerizable monomer to an area that is afflicted with or susceptible to oral fungal infection; andb) allowing said polymerizable monomer composition to polymerize to form a poly
1. A method of treating or preventing oral fungal infection, comprising:a) applying an adhesive composition comprising a polymerizable monomer to an area that is afflicted with or susceptible to oral fungal infection; andb) allowing said polymerizable monomer composition to polymerize to form a polymer film over said area,where said polymerizable monomer composition comprises an α-cyanoacrylate monomer. 2. The method of claim 1, wherein said method is for treating oral fungal infection, and said area is afflicted with an oral fungal infection. 3. The method of claim 1, wherein said method is for preventing oral fungal infection, and said area is susceptible to oral fungal infection. 4. The method of claim 1, wherein said monomer composition comprises at least one member selected form the group consisting of ethyl cyanoacrylate, butyl cyanoacrylate, and 2-octyl cyanoacrylate. 5. The method of claim 1, further comprising combining an anti-fungal agent with the polymerizable monomer composition on the area so that the at least one agent serves as a polymerization initiator for said polymerizable monomer composition. 6. The method of claim 1, wherein said composition further comprises at least one stabilizing agent for said polymerizable monomer. 7. The method of claim 6, wherein said stabilizing agent is also an anti-fungal agent. 8. The method of claim 1, wherein said composition comprises at least one plasticizer. 9. The method of claim 8, wherein the plasticizer is selected from the group consisting of tributyl citrate, acetyl tributyl citrate, polymethylmethacrylate, polydimethylsiloxane and hexadimethylsilazane. 10. The method of claim 1, wherein the composition further comprises an anti-fungal agent. 11. The method of claim 10, wherein said method is for treating oral fungal infection, and said area is afflicted with an oral fungal infection. 12. The method of claim 10, wherein said method is for preventing oral fungal infection, and said area is susceptible to oral fungal infection. 13. The method of claim 10, wherein said anti-fungal agent is selected from the group consisting of parabens, cresols, azoles, allylamines, pollyenes, acidics, mercurials, quaternary ammonium compounds, and non-polymer-stabilized compounds. 14. The method of claim 10, wherein said anti-fungal agent is a paraben selected from the group consisting of alkyl parabens having an alkyl group of from 1-4 carbon atoms. 15. The method of claim 10, wherein said anti-fungal agent is selected from the group consisting of methylparaben, methylparaben sodium, ethylparaben, propylparaben, propylparaben sodium, butylparaben, cresol, chlorocresol, voriconazole, ketoconazole, fluconazole, itraconazole, miconazole, clotrimazole, saperconazole, neticonazole, oxiconazole, isoconazole, sulconazole, tercanazole, tioconazole, naftifine, SF86-327, nyastatin, amphotericin B, pimaricin, benzoic acid and salts thereof, sorbic acid and salts thereof, propionic acids and salts thereof, boric acid and salts thereof, dehydroacetic acid, sulphurous and vanillic acids, alkyl esters of pararhydrobenzoic acid, thiomersal, phenylmercuric borate, phenylmercuric acetate and phenylmercuric nitrate, nitromersol, sodium ethylmercurithiosalicylate, benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, cetyltrimethyl ammonium bromide, hydroquinone, pyrocatechol, resorcinol, 4-n-hexyl resorcinol, 3a,4,7,7a-tetrahydro-2-((trichloromethyl)thio)-1H-isoindole-1,3(2H)-dione, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, dehydroacetic acid, o-phenylphenol, phenol, phenylethyl alcohol, potassium benzoate, potassium sorbate, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol, chlorothymol, alcohols, chlorobutanol, phenoxy-2-ethanol, benzyl alcohol, β-phenylethyl alcohol, chlorhexidine, 6-acetoxy-2,4-dimethyl-m-dioxane 2,4,4′trichloro-2′-hydroxy -diphenylether, imidizoldinylether urea compound, bromo-2-nitropropanediol-1,3 5-bromo-5-nitrol-1,3 dioxane, 2-methyl 1-4-isothiazolin-3-one and 5 chloro derivative, 1-(3-chloroallyl)-3,5,7-triazo 1-azoniaadamantane chloride, formaldehyde, imidazolidinyl urea, morpholines, salicylic acids, benzoic acids, sodium iodides and potassium iodides, flucytosine, 5-flucytosine, griseofulvin, terbinafine, cidofovir, famicoclovir, valacyclovir, echinocandins, pneumocandins, pradimicins, benanomicins, nikkomycins, amorolfine, polyoxins, duanorubicin citrate, doxorubicin hydrocholride, tolnaftate, ciclopirox, butenafine, ergestrol biosynthesis inhibitors, acrisorein, 3-amino-4-hydroxybutyric acid, ammonium mercuric chloride, amorolfine, anthralin, azaserine, bifonazole, biphenamine, bromosalicylchloranilide, buclosamide, butoconazole, calcium propionate, candicidin, chlordantoin, chlormidazole, chlorphenesin, chlorquinaldol, cloconazole, cloxyquin, coparaffinate, m-cresyl acetate, cupric sulfate, dermostatin, diamthazole dihydrochloride, econazole, enilconazole, etisazol, exalamide, fenticonazole, filipin, flutrimazole, fungichromin, hachimycin, halethazole, hamycin, hexetidine, lanoconazole, loflucarban, lucensomycin, Magenta I, mepartricin, 2-(methoxymethyl)-5-nitrofuran, monensin, myxin, natamycin, neomycin undecylenate, nifuratel, oligomycins, omoconazole, ontianil, pecilocin, perimycin, pyrithione, pyrrolnitrin, rubijervine, salicylanilide, sertaconzole, siccanin, sulbentine, tenonitrozole, tolciclate, tolindate, triacetin, 2,4,6-tribromo-m-cresol, tubercidin, ujothion, undecylenic acid, viridin, and zinc propionate. 16. The method of claim 10, wherein said anti-fungal agent is selected from the group consisting of cresol, clotrimazole, tolnaftate, terbinafine and tioconazole. 17. The method of claim 10, wherein said anti-fungal agent is selected from the group consisting of benzoic acid and salts thereof, sorbic acid and salts thereof, propionic acid and salts thereof, boric acid and salts thereof, dehydroacetic acid, sulphurous acids, vanillic acids, phenol, cresol, chlorocresol, o-phenylphenol, chlorothymol, parabens, alkyl esters of parahydroxybenzoic acid, methyl-p-hydroxybenzoates, ethyl-p-hydroxybenzoates, propyl-p-hydroxybenzoates, benzyl-p-hydroxybenzoates and butyl-p-hydroxybenzoates, thimersal, phenylmercuric acetate and phenylmercuric nitrate, nitromersol, sodium ethylmercurithiosalicylate, benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, cetyltrimethyl ammonium bromide, chlorobutanol, phenoxy-2-ethanol, benzyl alcohol, β-phenylethyl alcohol, chlorohexidine, chloroform, 6-acetoxy-2,4-dimethyl-m-dioxane, 2,4,4′trichloro-2′-hydroxy-diphenylether, imidizolidinyl urea compound, bromo-2nitropropanediol-1,3,5-bromo-5-nitrol-1,3 dioxane, 2-methyl-4-isothiazolin-3-one and 5 chloro derivative, and 1-(3-chloroallyl)-3,5,7-triazo 1-azoniaadamantane chloride. 18. The method of claim 10, wherein said anti-fungal agent is selected from the group consisting of miconazole nitrate, povidone iodine complex, cliquinol, haloprogin, tolnaftate and undecylenic acid and mixtures thereof. 19. The method of claim 10, wherein the anti-fungal agent is mixed with the polymerizable monomer composition immediately prior to applying the polymerizable monomer composition to the area. 20. The method of claim 10, wherein the anti-fungal agent is mixed with the polymerizable monomer composition during manufacture of the polymerizable monomer composition. 21. The method of claim 10, wherein said anti-fungal agent is a phenolic antioxidant. 22. The method of claim 10, wherein said antioxidant is a stabilizing agent for said monomer. 23. The method of claim 10, wherein said anti-fungal agent is butylparaben. 24. The method of claim 1, wherein said composition has a Sterility Assurance Level (SAL) of 10 −3 -10 −6 . 25. The method of claim 1, further comprising applying an anti-fungal agent to the area b efore applying the adhesive composition. 26. The method of claim 25, wherein said method is for treating oral fungal infection, and said area is afflicted with an oral fungal infection. 27. The method of claim 25, wherein said method is for preventing oral fungal infection, and said area is susceptible to oral fungal infection. 28. The method of claim 25, further comprising allowing the applied anti-fungal agent to substantially dry before applying the adhesive composition. 29. The method of claim 25, wherein the anti-fungal agent is selected from the group consisting of parabens, cresols, and non-polymer-stabilized compounds. 30. The method of claim 25, wherein the anti-fungal agent is selected from the group consisting of alkyl parabens having an alkyl group of from 1-4carbon atoms. 31. The method of claim 25, wherein the anti-fungal agent is selected from the group consisting of methylparaben, methylparaben sodium, ethylparaben, propylparaben, propylparaben sodium, butylparaben, cresol, chlorocresol, voriconazole, ketoconazole, fluconazole, itraconazole, miconazole, clotrimazole, saperconazole, neticonazole, oxiconazole, isoconazole, sulconazole, tercanazole, tioconazole, naftifine, SF86-327, nyastatin, amphotericin B, pimaricin, benzoic acid and salts thereof, sorbic acid and salts thereof, propionic acids and salts thereof, boric acid and salts thereof, dehydroacetic acid, sulphurous and vanillic acids, alkyl esters of pararhydrobenzoic acid, thimerosal, phenylmercuric borate, phenylmercuric acetate and phenylmercuric nitrate, nitromersol, sodium ethylmercurithiosalicylate, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, dehydroacetic acid, o-phenylphenol, phenol, phenylethyl alcohol, potassium benzoate, potassium sorbate, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol, chlorothymol, alcohols, chlorobutanol, phenoxy-2-ethanol, benzyl alcohol, β-phenylethyl alcohol, chlorhexidine, 6-acetoxy-2,4-dimethyl-m-dioxane 2,4,4′trichloro-2′-hydroxy-diphenylether, imidizoldinylether urea compound, bromo-2-nitropropanediol-1,3 5-bromo-5-nitrol-1,3 dioxane, 2-methyl 1-4-isothiazolin-3-one and 5 chloro derivative, 1-(3-chloroallyl)-3,5,7-triazo 1-azoniaadamantane chloride and formaldehyde, imidazolidinyl urea, morpholines, salicylic acids, benzoic acids, sodium iodides, potassium iodides, flucytosine, 5-flucytosine, griseofulvin, terbinafine, cidofovir, famicoclovir, valacyclovir, echinocandins, pneumocandins, pradimicins, benanomicins, nikkomycins, amorolfine, polyoxins, duanorubicin citrate, doxorubicin hydrocholride, tolnaftate, ciclopirox, butenafine, ergestrol biosynthesis inhibitors, acrisorein, 3-amino-4-hydroxybutyric acid, ammonium mercuric chloride, amorolfine, anthralin, azaserine, bifonazole, biphenamine, bromosalicylchloranilide, buclosamide, butoconazole, calcium propionate, candicidin, chlordantoin, chlormidazole, chlorphenesin, chlorquinaldol, cloconazole, cloxyquin, coparaffinate, m-cresyl acetate, cupric sulfate, dermostatin, diamthazole dihydrochloride, econazole, enilconazole, etisazol, exalamide, fenticonazole, filipin, flutrimazole, fungichromin, hachimycin, halethazole, hamycin, hexetidine, lanoconazole, loflucarban, lucensomycin, Magenta I, mepartricin, 2-(methoxymethyl)-5-nitrofuran, monensin, myxin, natamycin, neomycin undecylenate, nifuratel, oligomycins, omoconazole, ontianil, pecilocin, perimycin, pyrithione, pyrrolnitrin, rubijervine, salicylanilide, sertaconzole, siccanin, sulbentine, tenonitrozole, tolciclate, tolindate, triacetin, 2,4,6-tribromo-m-cresol, tubercidin, ujothion, undecylenic acid, viridin, and zinc propionate. 32. The method of claim 25, wherein the anti-fungal agent is selected from the group consisting of elemental metals and metal compounds. 33. The method of claim 25, wherein the anti-fungal agent further comprises at least one of a diluent and a carrier. 34. The method of claim 25, wherein the anti-fungal agent is in the form of a liquid, a solid, a powder, or a cream. 35. The method of claim 25, wherein the anti-fungal agent is selected from the group consisting of miconazole nitrate, povidone iodine complex, cliquinol, haloprogin, tolnaftate and undecylenic acid and mixtures thereof. 36. The method of claim 1, wherein said adhesive composition is applied directly to said area, and said adhesive composition does not include an anti-fungal agent. 37. The method of claim 36, wherein said polymer film has anti-fungal effects at said area. 38. A method of treating or preventing, the method comprising the steps of:a. applying an anti-fungal agent to an area that is afflicted with or susceptible to oral fungal infection;b. applying a polymerizable monomer composition to said area over the applied anti-fungal agent, wherein said composition comprises an α-cyanoacrylate monomer; andc. allowing said polymerizable monomer composition to polymerize to form a polymer film over said area and said anti-fungal agent. 39. The method of claim 38, wherein said method is for treating oral fungal infection, and said area is afflicted with an oral fungal infection. 40. The method of claim 38, wherein said method is for preventing oral fungal infection, and said area is susceptible to oral fungal infection. 41. A method of treating or preventing oral fungal infection, the method comprising:a. combining a polymerizable monomer composition and an anti-fungal agent to form a mixture;b. applying said mixture to an area that is afflicted with or susceptible to oral fungal infection; andc. allowing said mixture to polymerize to form an anti-fungal containing polymer film over said area,wherein said polymerizable monomer composition comprises an α-cyanoacrylate monomer. 42. The method of claim 41, wherein said method is for treating oral fungal infection, and said area is afflicted with an oral fungal infection. 43. The method of claim 41, wherein said method is for preventing oral fungal infection, and said area is susceptible to oral fungal infection. 44. The method of claim 1, wherein said area comprises mucous membranes in a patient's oral cavity. 45. The method of claim 38, wherein said area comprises mucous membranes in a patient's oral cavity. 46. The method of claim 41, wherein said area comprises mucous membranes in a patient's oral cavity. 47. The method of claim 1, wherein said method is for preventing spread of an established oral fungal infection, and said area is suseceptible to oral fungal infection. 48. The method of claim 38, wherein said method is for preventing spread of an established oral fungal infection, and said area is susceptible to oral fungal infection. 49. The method of claim 41, wherein said method is for preventing spread of an established oral fungal infection, and said area is susceptible to oral fungal infection.
Lucast Donald H. (North St. Paul MN) Calhoun Clyde D. (Stillwater MN) Riedel John E. (Hugo MN) Taylor Charles W. (Lake Elmo MN), Adhesive sheet material suitable for use on wet surfaces.
Akimova Alla Y. (ulitsa Petrozavodskaya ; 5 ; korpus 3 ; kv. 391 Moscow SUX) Davydov Anatoly B. (ulitsa Krasny Kazanets ; 19 ; korpus 1 ; kv. 283 Moscow SUX) Egiev Valery N. (Volgogradsky prospekt ; , Biocompatible material for treatment of tissular or organic defects.
Akimova Alla Y. (Moscow SUX) Buyanov Valentin M. (Moscow SUX) Galperin Eduard I. (Moscow SUX) Davydov Anatoly B. (Moscow SUX) Derkach Galina M. (Moscow SUX) Derevyanko Vitaly P. (Moscow SUX) Keshelav, Composition for sealing wound surfaces.
Greff Richard J. (Yorba Linda CA) Tighe Patrick J. (Littleton CO) Byram Michael M. (Colorado Springs CO) Barley Leonard V. (Colorado Springs CO), Cyanoacrylate adhesive compositions.
Greff Richard J. (Yorba Linda CA) Tighe Patrick J. (Littleton CO) Byram Michael M. (Colorado Springs CO) Barley Leonard V. (Colorado Springs CO), Cyanoacrylate adhesive compositions.
Melanson David A. ; Sawhney Amarpreet S. ; Levine Marc Alan ; Spiridigliozzi John C. ; Bromander Thomas S., Initiator priming for improved adherence of gels to substrates.
Tighe Patrick J. (Littleton CO) Byram Michael M. (Colorado Springs CO) Barley ; Jr. Leonard V. (Colorado Springs CO), Methods for inhibiting skin ulceration by use of cyanoacrylate adhesives.
Barley ; Jr. Leonard V. (Colorado Springs CO) Tighe Patrick J. (Littleton CO) Greff Richard J. (Yorba Linda CA) Byram Michael M. (Colorado Springs CO), Methods for reducing skin irritation from artificial devices by use of cyanoacrylate adhesives.
Greff Richard J. ; Byram Michael M., Methods for treating non-suturable, superficial wounds by use of cyanoacrylate ester compositions comprising an antimi.
Barley Linda M. (Colorado Springs CO) Renfrow J. Royce (Mt. Crested Butte CO) Byram Michael (Colorado Springs CO), Methods for treating suturable wounds by use of sutures and cyanoacrylate adhesives.
Berglund Claire A. (Shoreview MN) Rosso Paul D. (St. Joseph Township ; St. Croix County WI), Pressure-sensitive adhesive having a broad spectrum antimicrobial therein.
McDonnell Patrick F. (Dublin IEX) Lambert Robert J. (County Dublin IEX), Sterilized cyanoacrylate adhesive composition, and a method of making such a composition.
Byram Michael M. (Colorado Springs CO) Goebel Robert (Huntington Beach CA) Greff Richard J. (Yorba Linda CA) Barley ; Jr. Leonard V. (Littleton CO), Use of cyanoacrylate adhesive compositions to inhibit acute radiation-induced skin damage.
Tighe Patrick J. (Littleton CO) Greff Richard J. (Yorba Linda CA) Byram Michael M. (Colorado Springs CO) Barley Leonard V. (Colorado Springs CO), Use of cyanoacrylate adhesives for providing a protective barrier film for the skin.
Chvapil Milos (Tucson AZ) Hoenig Stuart A. (Tucson AZ), Use of hydrogel solutions to form a hydrophilic protective film on the skin against toxic substances, pollutants, infect.
Zhang, Sheng; Ruiz, Rafael, Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator.
Burrell, Janna M.; Byrum, Randal T.; Koch, Jr., Robert Louis; Pool, Larry D.; Widenhouse, Christopher W., Methods and devices for treating morbid obesity using hydrogel.
Faller, Craig N.; Haberstitch, Wells D.; Korvick, Donna L.; Thompson, Bennie; Turner, Douglas J.; Nalagatla, Anil K.; Shelton, IV, Frederick E., Use of an adhesive to treat intraluminal bleeding.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.